Sort   by:  
 Page size 
GenomicsGenetic mapping and characterisation of triclabendazole resistance in the liver fluke, Fasciola hepatica
Mapping triclabendazole resistance in Fasciola
PRJEB50899 | ENA
Genomics
Triclabendazole Resistant Fascioliasis
PRJNA916254 | ENA
UnknownTriclabendazole Induces Pyroptosis by Activating Caspase-3 to Cleave GSDME in Breast Cancer Cells.
Not available
S-EPMC8297466 | biostudies-literature
UnknownTriclabendazole inhibits PKM2 nuclear localization and glycolysis by enhancing HDAC6-mediated deacetylation in lung cancer.
Not available
S-EPMC12461981 | biostudies-literature
UnknownEfficacy of flukicides against Fasciola hepatica and first report of triclabendazole resistance on German sheep farms.
Not available
S-EPMC10757264 | biostudies-literature
UnknownTriclabendazole suppresses cellular levels of glycosaminoglycan-A potential therapeutic agent for mucopolysaccharidoses and related diseases.
Not available
S-EPMC12355420 | biostudies-literature
UnknownIn Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Not available
S-EPMC6416464 | biostudies-literature
UnknownThe small molecule triclabendazole decreases the intracellular level of cyclic AMP and increases resistance to stress in Saccharomyces cerevisiae.
Not available
S-EPMC3648474 | biostudies-literature
UnknownEffects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.
Not available
S-EPMC10582667 | biostudies-literature
Genomics
Parasite Genomic and Host Microbiome Determinants of Triclabendazole Treatment Failure in Fascioliasis
PRJNA1467721 | ENA
Sort   by:  
 Page size